GlassScriptPhysician profile
Sutha Sachar
NPI 1033181573
$9,297.51
in general payments reported to CMS, 2019-2025
37 companies · $2,136 in 2025
The $2,136 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $1,081 · 2021: $1,449 · 2022: $995 · 2023: $1,184 · 2024: $1,617 · 2025: $2,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,936.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.51 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $958.31 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $889.13 | 2019-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $810.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $700.84 | 2019-2023 | Wegovy, Saxenda |
| Gilead Sciences, INC. | $561.85 | 2021-2025 | Livdelzi |
| Redhill Biopharma INC. | $383.73 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Aimmune Therapeutics, INC. | $323.17 | 2024-2025 | Zenpep, Vowst |
| Allergan, INC. | $313.59 | 2019-2022 | |
| Galderma Laboratories, L.P. | $305.39 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $283.84 | 2024-2025 | Voquezna |
| Merz North America, INC. | $250.47 | 2019-2023 | Xeomin |
| Qol Medical, LLC | $248.07 | 2021-2024 | Sucraid |
| Braintree Laboratories, INC. | $209.71 | 2019-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $186.24 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $172.65 | 2019-2024 | Qsymia |
| Ardelyx, INC. | $158.89 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $147.72 | 2023 | |
| Exact Sciences Corporation | $113.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $113.14 | 2019-2024 | Dificid |
| Alfasigma USA, INC. | $107.87 | 2020-2021 | |
| Lilly USA, LLC | $101.21 | 2024-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $91.38 | 2019-2025 | Entyvio |
| Currax Pharmaceuticals LLC | $84.93 | 2022-2024 | Contrave |
| Solta Medical, A Division of Bausch Health US, LLC | $79.65 | 2020-2022 | |
| Shield Therapeutics INC | $58.58 | 2024-2025 | |
| Lucid Diagnostics INC. | $57.10 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.82 | 2020 | |
| Incyte Corporation | $40.18 | 2022 | |
| Genzyme Corporation | $35.04 | 2024 | |
| Capsovision, INC. | $34.39 | 2025 | Capsocam Plus |
| Amag Pharmaceuticals, INC. | $30.83 | 2022 | |
| Daiichi Sankyo INC. | $29.37 | 2021-2022 | |
| Alk-Abello, INC | $28.77 | 2025 | Ragwitek, Odactra, Grastek |
| Astrazeneca Pharmaceuticals LP | $24.71 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.42 | 2025 | Rebyota |
| Revance Therapeutics, INC. | $17.06 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sutha Sachar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.